Home » Newsletters » BioWorld

BioWorld

Jan. 9, 2001

View Archived Issues

DNA Sciences Seeks $125M In IPO For Genetics Discovery

Other News To Note

Cubist Getting Up To $44M From Gilead Through Daptomycin Deal

NeoGenesis Raises $23M In 4th Round To Fund Programs

Syrrx Raises $54M Privately For Protein Structure Determination

FDA Denies Approval Of Aronex's Atragen; Stock Falls 73 Percent

Ligand Completes $24M Private Financing For Various Programs

Three Friendly Rivals Unanimous: Seek Major AD Risk-Factor Gene On Chromosome 10 Hotspot Site

OSI's Double Deal For Cancer Drug: Genentech, Roche Pay Up To $187M

Genentech CEO: Keep It Simple - And Give Up On Trial Failures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026